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Abstract
Malignant melanoma is the most deadly form of skin cancer. There is a critical need to identify the patients that could 
be successfully treated by surgery alone and those that require adjuvant treatment. In this study, we demonstrate that 
the expression of tribbles2 (TRIB2) strongly correlates with both the presence and progression of melanocyte-derived 
malignancies. We examined the expression of TRIB2 in addition to 12 previously described melanoma biomarkers across 
three independent full genome microarray studies. TRIB2 expression was consistently and significantly increased in benign 
nevi and melanoma, and was highest in samples from patients with metastatic melanoma. The expression profiles for 
the 12 biomarkers were poorly conserved throughout these studies with only TYR, S100B and SPP1 showing consistently 
elevated expression in metastatic melanoma versus normal skin. Strikingly we confirmed these findings in 20 freshly 
obtained primary melanoma tissue samples from metastatic lesions where the expression of these biomarkers were 
evaluated revealing that TRIB2 expression correlated with disease stage and clinical prognosis. Our results suggest that 
TRIB2 is a meaningful biomarker reflecting diagnosis and progression of melanoma, as well as predicting clinical response 
to chemotherapy.
Introduction
Malignant melanoma is a highly aggressive cancer that arises 
from the transformation of melanocytes, the pigment-produc-
ing cells within the basal epidermal layer in human skin (1). 
Malignant melanoma accounts for only 5% of all skin cancers, 
yet is responsible for 80% of skin cancer deaths. Furthermore, 
the incidence of metastatic melanoma has increased over the 
past three decades with a mortality rate that continues to rise 
faster than almost all other cancers (2). This combination of 
aggressive clinical behaviour, propensity for metastasis and 
therapeutic resistance has motivated efforts to translate our 
growing knowledge into more effective treatments. Where pos-
sible, disease management incorporates the wide local excision 
of the tumour offering a 95% 5-year survival for patients with 
localized melanoma (3). However, this option is restricted due 
to late stage diagnosis and tumour metastasis. In addition, dis-
ease relapse is frequent resulting in an extremely poor clinical 
prognosis. Currently, the established treatment of metastatic 
melanoma includes high-dose interleukin-2 or dacarbazine 
administration associated with response rates of between 10 
and 20% with severe patient side effects during treatment (4–
6). Recently, two promising groups of therapeutics, the kinase 
inhibitors (vemurafenib, dabrafenib and trametinib), and the 
immune checkpoint blockers (ipilimumab) were approved 
by the FDA and the EMA (7,8). These therapies might prove 
to be a breakthrough for late stage melanoma treatment but 
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accurate predictive classification of melanoma would allow for 
the identification of the patient population that would benefit 
from systemic therapy, minimizing the unnecessary suffering 
of patients from therapeutic side effects as well as excessive 
treatment costs.
Currently, melanoma patients are divided into four stages. 
These are based on Breslow tumour thickness, the presence 
of ulceration, the extent of nodal involvement for primary and 
locally metastatic cutaneous melanoma, serum lactate dehy-
drogenase (LDH) level and sites of metastasis for systemic dis-
ease (9). To improve diagnosis and staging of melanoma, the use 
of several molecular tissue and serum biomarkers have been 
investigated (10). At present, serum LDH is the only molecular 
marker that has been incorporated into routine disease stag-
ing with many others at various stages of validation. Of these 
biomarkers, the most intensively examined is the beta subu-
nit of the acidic calcium binding protein S100 calcium binding 
protein B (S100B). S100B expression has been shown to corre-
late with survival, recurrence and clinical melanoma stage (low 
protein expression in stages I and II, elevated protein expres-
sion in stage III and highest protein levels in stage IV) (11,12). 
While promising, the absence of a standardized protocol for the 
analysis of serum samples and S100B measurement impede the 
evaluation of this marker across different studies. As a result, 
the application of S100B as a routine clinical serum marker of 
melanoma is still not established. Similarly, tyrosinase oculocu-
taneous albinism IA (TYR), a tissue specific enzyme involved in 
melanin synthesis (13) has also emerged as a means to detect 
malignant melanoma cells either within peripheral blood or 
regional lymph nodes (14). A  number of groups have demon-
strated that TYR is a reliable factor associated with response 
to treatment, development of metastases, disease progression 
and overall survival (15) although this is controversial (16). 
Consequently, the evaluation of standardized protocols for PCR-
based techniques in comparison to those available for stand-
ardized measurement of enzyme activities or (specific) protein 
concentration is required. In addition to these two biomarkers 
there are a number of less extensively investigated melanoma 
molecular biomarkers (summarized in Supplementary Table 1, 
available at Carcinogenesis Online (12,13,17–26)) that have been 
associated with disease progression, disease stage and/or clini-
cal outcome. While these represent promising biomarkers, the 
clinical value of these molecular targets is limited by the inher-
ent heterogeneity of molecular melanoma signatures as well 
as by an insufficient selectivity and sensitivity. Consequently, 
there is an urgent need for better, more robust molecular bio-
markers to precisely diagnose disease stage, refine the risk of 
disease progression and accurately predict disease response to 
therapy.
In this study, we evaluated the potential of tribbles2 (TRIB2) 
as a novel molecular melanoma biomarker. The kinase-like 
protein TRIB2 was found to be highly expressed specifically in 
melanoma and can facilitate the growth and survival of melano-
mas by down regulating FOXO activity (17). Here, we show that 
TRIB2 can serve as a biomarker of high accuracy to detect the 
presence and progression of human melanoma. In comparison 
with 12 previously described melanoma markers, we show that 
TRIB2 expression provides the second most accurate marker to 
identify melanoma formation and progression. Crucially, we 
confirmed these results in ex vivo clinical samples, implicating 
TRIB2 status affecting clinical prognosis.
Materials and methods
Datasets used for the analysis
For analysis, microarray data for human normal skin, benign nevi, 
primary and metastatic melanoma samples from three independent 
studies were utilized [Talantov et  al. (27) (GSE3189), Smith et  al. (28) 
(GSE4587) and Riker et al. (29) (GSE7553)]. Talantov et al. (GSE3189) used 
Affymetrix Hu133A GeneChips to identify molecular markers for lymph 
node staging in melanoma tumourigenesis. The dataset consists of 7 
normal skin, 18 nevi and 45 melanoma samples. Smith et  al. dataset 
(GSE4587) comprise 2 normal skin, 4 nevi, 2 melanoma in situ and 7 
melanoma samples. These different sample classes are summarized in 
Supplementary Table 2, available at Carcinogenesis Online. Gene expres-
sion study was carried out using Affymetrix Human Genome U133 Plus 
2.0 Chip to identify molecular changes at the transition of melanoma in 
situ into metastatic melanoma. The third dataset derived from the Riker 
et al. (GSE7553) study were conducted using Affymetrix Human Genome 
U133 Plus 2.0 Chips. This dataset comprises 15 basal cell carcinoma, 
11 squamous cell carcinoma, 14 primary melanoma and 40 metastatic 
melanoma samples. Importantly, all of the genes present in Affymetrix 
Human Genome U133A array [also used in the Talantov et al. (GSE3189) 
study] are present in the Affymetrix Human Genome U133 Plus 2.0 array 
[utilised in both the Riker et  al. (GSE7553) and Smith et  al. (GSE4587) 
reports]. All of the bio-markers investigated in our study are present in 
both array platforms.
Datasets pre-processing and analysis
Expression data were obtained from Gene Expression Omnibus database 
(accession numbers: GSE3189, GSE4587, GSE7553). Data analysis was car-
ried out in the R/Bioconductor environment. In particular, data pre-pro-
cessing, normalization and summary index calculation was performed 
using the RMA (Robust Multi-array Average) method as implemented 
in the Bioconductor affy package with a default parameter setting. The 
Bioconductor limma package was utilised to detect differential expression 
in metastatic melanoma compared with their corresponding controls. 
To correct for multiple testing, Benjamini and Hochberg procedure was 
applied (30). For identification of differentially regulated genes, adjusted 
P-value ≤0.05 and absolute log2 fold change ≥1.0 was set as criteria. To 
assess the statistical significance of common up- or down-regulated genes 
in the three microarray datasets, the hypergeometric test (which is equiv-
alent to Fisher’s exact test) was applied.
Receiver operating characteristic curve analysis
To stringently assess the capacity of compared biomarkers for melanoma 
diagnosis and staging, receiver operating characteristic (ROC) curves 
were constructed. ROC curves display the sensitivity and specificity of 
biomarkers across a maximal range of threshold settings and are stand-
ard means for the comparison of classifiers. In our case, samples were 
classified based on the expression levels of marker genes with respect 
to the chosen threshold. Comparison of the achieved classification with 
the known samples classes (e.g. normal tissue, nevi or melanoma) pro-
vided the number of true positives (TP), false positives (FP), false nega-
tives (FN) and true negatives (TN). The sensitivity or true positive rate 
(TPR) is defined as TPR = TP/(TP + FN), whereas false positive rate (FPR), 
that is 1-specificity is given by FPR = FP/(FP + TN). For each microarray 
studies, TPR and FPR were recorded across a maximal range of expression 
threshold values for individual biomarker and displayed as ROC curves. 
As overall measure for classification performance, the total area under 
the ROC curve (AUC) was calculated. The AUC is equivalent to the aver-
age sensitivity across the full range of specificity values and can have a 
maximum value of 1. AUC was derived for each of the constructed ROC 
curves, that is for each biomarker and each of the sample classifications. 
Abbreviations  
AUC  area under the curve 
ROC  receiver operating characteristic
S100B  S100 calcium binding protein B
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For comparison, the biomarkers were ranked according to their average 
AUC in the three datasets.
The Cancer Genome Atlas database analysis
We performed our analysis on skin cutaneous melanoma (SKCM) data sets 
available in The Cancer Genome Atlas (TCGA) data portal (https://tcga-
data.nci.nih.gov/tcga/). We downloaded the all the 385 files from TCGA 
data portal (https://tcga-data.nci.nih.gov/tcga/) and extracted normalized 
counts computed using RSEM software (PMID: 21816040) from these into 
a data matrix. Further, we mapped sample annotations for the individual 
datasets to perform several comparisons such as patient survival (alive or 
dead), Clark’s level of invasion and Breslow’s depth.
Quantitative real-time PCR
Total RNA was extracted from our clinical samples using Tri-reagent 
(Sigma). Real-time PCR was performed on a CFX-96 PCR machine (BioRad) 
using the SSoFastSybr® green master mix (BioRad) and following the 
manufactures guidelines. The primer sequences for measuring all of our 
genes of interest were purchased from NZYTech (Portugal) and are shown 
in Supplementary Table  3, available at Carcinogenesis Online. All expres-
sion analysis for each clinical sample was conducted in quadruplicate. 
Normalization was carried out against GAPDH and data analysis utilised 
the 2−∆∆Ct  methodology, described by Livak et al. (31).
Statistical analysis
All statistical analysis conducted following qRT-PCR used unpaired two-
tailed student t-test (Graph pad PRISM) generating a P value for each com-
parison. Values ≤0.05 were considered significant in our analysis although 
for each calculation, the P value is clearly indicated. Where N/S is indi-
cated, the P value is not significant.
Clinical sample analysis
Surgically excised tissue samples from metastatic lesions of stage IV 
melanoma patients prior to first-line therapy were freshly frozen and 
cryo-preserved until processing. The collection and the documentation of 
clinical samples were performed after obtaining informed consent with 
Institutional Review Board approval. Specifically, study #123/2008 was 
under taken with Ethics Committee approval from the Ethics Committee 
Faculty of Medicine, University of Wuerzburg, Germany. The frozen tis-
sues were split into smaller sections for RNA extraction using TRI-Reagent 
(Sigma).
Results
To address if TRIB2 could be a melanoma biomarker we exam-
ined three independent whole genome microarray studies that 
contained a large number of samples in each disease grade (nor-
mal skin, benign nevi, basal cell carcinoma, squamous cell carci-
noma, primary melanoma and metastatic melanoma).
Poor melanoma biomarker correlation across each 
data set
Our first objective was to obtain an overview of the global 
changes in gene expression within each genome wide study. 
We identified the differentially expressed genes in each com-
plete data set incorporating a 2-fold increase or decrease in 
gene expression as the expression change threshold for our 
analysis, comparing normal skin versus nevus, primary mela-
noma or metastatic melanoma samples from the Talantov et al. 
(GSE3189) and Smith et al. (GSE4587) studies and from the Riker 
et al. (GSE7553) study comparing basal carcinoma versus squa-
mous, melanoma and metastatic melanoma samples. For statis-
tical rigor and robustness we also required an adjusted P-value 
of less than 0.05 for each gene of interest that showed a 2-fold 
expression change. Across all of the genome wide studies, we 
found that 86 genes were consistently up-regulated while the 
expression of 222 genes was significantly reduced in each inde-
pendent study (summarized in Figure 1A and B, Supplementary 
Figure 1. Venn diagram and Volcano plots indicating the differentially regulated genes across each data set. [Talantov et al. (GSE3189), Smith et al. (GSE4587) and Riker 
et al. (GSE7553)]. (A) Conserved up regulated genes. (B) Conserved down regulated genes. (C) Talantov et al. (GSE3189), D. Smith et al. (GSE4587) and E. Riker et al. (GSE7553). 
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Tables 4 and 5, available at Carcinogenesis Online). It is important 
to note that while the number of genes with a conserved expres-
sion pattern across every study was low, these gene expression 
changes were highly significant (P-value = 1.63E−10, 1.10E−4 and 
5.00E−3, respectively). We also note that while their expression 
changes were not conserved between each study, all 12 bio-
markers (as well as TRIB2) were present in either the up-regu-
lated or down-regulated gene list (and therefore are present in 
either Venn diagram).
We next questioned if the transcription of the 12 putative 
melanoma biomarkers changed from normal to metastatic 
melanoma disease state. We note that only S100B, SPP1 and 
ING4 displayed a conserved statistically significant expression 
change from normal skin to metastatic melanoma in all of the 
data sets (Supplementary Table  6, available at Carcinogenesis 
Online). While we observe a poor correlation between the 12 
melanoma biomarkers across each genome wide array, we noted 
that TRIB2 transcription was both consistently and significantly 
increased across all three studies. Furthermore, despite the bio-
markers S100B, SPP1 and ING4 showing a statistically significant 
expression difference across every microarray, only S100B dis-
played a conserved increase in expression during transforma-
tion from control (normal skin or basal carcinoma) to metastatic 
melanoma. While ING4 demonstrated a statistically significant 
change between control and metastatic melanoma samples in 
each array study, the changes observed were however not con-
sistent. ING4 expression was drastically decreased in metastatic 
melanoma samples (compared with control groups) within the 
Riker et al. (GSE7553) study, yet it was significantly over-expressed 
in the Talantov et al. (GSE3189) and Smith et al. (GSE4587) studies. 
It should be noted that a potential caveat related to the Riker 
et al. study might be the use of basal cell carcinoma and squa-
mous cell carcinoma samples that are already transformed as 
controls for nonmelanoma skin cancer. This can account for 
the discrepancy noted for ING4 expression. However, while this 
was a concern for ING4, this difference (between Talantov et al. 
(GSE3189) and Smith et al. (GSE4587) compared with Riker et al. 
(GSE7553) was only noted for one additional biomarker (PTTG1, 
Supplementary Figure 1F, available at Carcinogenesis Online) and 
was not conserved for any other biomarkers where expression 
changes were conserved between Talantov et  al./Riker et  al. 
(ERBB3) or Smith et al./Riker et al. (HSP90AB1). Overall from this 
analysis, we can conclude that the expression profiles for each 
of the 12 melanoma biomarkers were poorly conserved across 
the three genome-wide microarray studies with only S100B 
and SPP1 demonstrating a conserved increase in transcription 
during carcinogenesis (from control to metastatic melanoma). 
Strikingly, TRIB2 transcription was significantly increased across 
all three independent data sets, suggesting that TRIB2 could be 
a melanoma biomarker.
Identification of TRIB2 as a biomarker indicating 
metastatic melanoma
To evaluate more stringently the potential of TRIB2 expres-
sion as a biomarker of metastatic melanoma, we analyzed dif-
ferential gene expression in each study using Volcano plots 
(Figure  1C–E). We ranked each biomarker (including TRIB2) 
within each microarray study and as we would have predicted 
following our global gene analysis, we noted that there was little 
conservation in expression between the 12 melanoma biomark-
ers in each data set. For example, the Talantov et al. (GSE3189) 
and Riker et al. (GSE7553) studies indicate that ING3 expression 
is reduced in metastatic melanoma in contrast to the Smith 
et al. (GSE4587) study that indicated the induction of this gene 
in metastatic melanoma samples. While there was little conser-
vation between these data sets, for each study, TRIB2 was sig-
nificantly over-expressed in a consistent manner and was in the 
top three of all over-expressed genes. Interestingly, in the Smith 
et al. (GSE4587) and Riker et al. (GSE7553) studies S100B was the 
most over-expressed biomarker in the metastatic melanoma 
samples. In the Talantov et al. (GSE3189) data set, TYR was the 
most over-expressed gene between normal skin versus meta-
static melanoma. Taking into consideration the inconsistent 
expression profiles of “bona fide” melanoma markers between 
these studies we are able to conclude that TRIB2 and specifically, 
the over-expression of TRIB2 is a strong melanoma biomarker 
candidate.
TRIB2 expression correlates with melanoma 
progression
Of equal interest and importance for a biomarker is the poten-
tial to differentiate various stages of disease. With this question 
in mind, we examined if TRIB2 expression could distinguish the 
various stages of melanoma progression (normal skin, nevus, 
primary melanoma and metastatic melanoma). To test this, we 
plotted the expression of TRIB2 as well as the three melanoma 
biomarkers (SPP1, S100B and ING4) that demonstrated a statisti-
cally significant transcription difference between normal skin 
versus metastatic melanoma samples (Figure  2A–D). We also 
plotted the fold expression changes for the remaining nine 
melanoma biomarkers (Supplementary Figure 1A–I, available at 
Carcinogenesis Online). For each biomarker that demonstrated an 
overall significant expression change between normal/basal tis-
sues compared with metastatic melanoma tissue, we conducted 
two-tailed unpaired t-tests to address if any of the melanoma 
biomarkers or TRIB2 could be used to determine melanoma 
stage. Of these four genes, TRIB2, S100B and SPP1 demonstrated 
a statistically significant increase in expression from the con-
trol groups (normal skin/basal carcinoma) versus metastatic 
melanoma in all three genome-wide array studies (Figure 2A–C). 
For the other biomarker [ING4 (Figure 2D)] we observe a highly 
significant difference in expression when we compare control 
samples versus metastatic melanoma; however there is no 
consistency for these genes between the microarray studies: 
For example, when we examine ING4 expression changes, the 
Talantov et al. (GSE3189) and Smith et al. (GSE4587) studies reveal 
a significant expression decrease from normal to metastatic 
melanoma, whereas the Riker et  al. (GSE7553) study reveals a 
highly significant induction of ING4 expression between basal 
and metastatic melanoma. We note significantly elevated TRIB2 
expression when normal skin versus nevus samples were ana-
lysed in addition to nevus versus melanoma TRIB2 expression 
particularly within the large Talantov et al. (GSE3189) study. Our 
analysis also identified that of all the previously described mela-
noma biomarkers, only S100B over-expression was as consist-
ently conserved as TRIB2. Based on these results, we were able 
to statistically rank the 12 melanoma markers evaluating the 
statistical significance of each gene expression change across 
all three microarray data sets and to incorporate TRIB2 into this 
analysis (Table 1). Equally when we considered only enhanced 
gene expression associated with increased melanoma grade 
in our analysis we found (including all 12 melanoma biomark-
ers) that TRIB2 over-expression was the second most conserved 
gene of all evaluated genes Table 2). These results show that 
TRIB2 expression is a highly promising biomarker of melanoma 
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TRIB2 is confirmed as a biomarker of melanoma 
progression via ROC analysis
A crucial caveat we next addressed was to critically evaluate 
the performance of TRIB2 as a biomarker for metastatic mela-
noma. To determine the strength of TRIB2 as a predictive marker 
we calculated the TPR and FPR specificity for TRIB2, S100B, 
SPP1 and ING4 from the three genome wide array studies. ROC 
curves were generated for each biomarker following our TPR 
and FPR analysis (Figure 2E). For the remaining biomarkers we 
also plotted ROC curves (Supplementary Figure  2, available at 
Figure 2. Expression and ROC curve analysis for TRIB2 and each melanoma biomarker within each data set [Talantov et al. (GSE3189), Smith et al. (GSE4587) and Riker 
et al. (GSE7553)]. A–D indicates the expression changes within each melanoma stage (normal/basal, nevus/squamous, melanoma or metastatic melanoma) for TRIB2, 
S100B, SPP1 and ING4. For each plot the x-axis shows the average log2 normalized gene expression (measured by quantification of the fluorescent signal from the 
microarray hybridization) from each set of samples on y-axis. E–G shows the classification performance of the molecular melanoma biomarker TRIB2, S100B, SPP1 and 
ING4 from each dataset [E. Talantov et al. (GSE3189), F. Smith et al. (GSE4587) and G. Riker et al. (GSE7553)]. On each plot, the x-axis indicates the TPR and sensitivity and 
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Carcinogenesis Online) and for every biomarker, including TRIB2 
we calculated the AUC. This analysis identified biomarker(s) 
that can classify each melanoma sample more effectively, 
where the higher the AUC value, the stronger and more robust 
the gene of interest. In all three datasets TRIB2 had a consist-
ently high AUC, [Talantov et al. (GSE3189) AUC = 0.963 (ranked 
third overall), Smith et al. (GSE4587) AUC = 0.916 (ranked sixth 
overall) and Riker et al. (GSE7553) AUC = 0.866 (ranked second 
overall)] and is summarized in Table 2. Importantly in large 
datasets [such as the Talantov et  al. (GSE3189) and Riker et  al. 
(GSE7553) studies] TRIB2 has a higher AUC than the majority of 
all other biomarkers examined suggesting that TRIB2 performs 
better in large datasets, an absolute prerequisite for a diagnostic 
biomarker. Our analysis also highlights that TRIB2 (with an aver-
age AUC = 0.9156) ranked second overall among all 12 biomark-
ers with only SPP1 (with an average AUC = 0.966) being ranked 
higher across three whole genome array studies. These results 
strongly support our previous findings that indicate TRIB2 as a 
very strong candidate for both the diagnosis and progression of 
melanoma disease.
TRIB2 expression is significantly increased in freshly 
obtained metastatic melanoma samples compared 
to normal skin
We next wanted to validate our results in freshly obtained clini-
cal samples from metastatic melanoma patients prior to stand-
ard systemic treatment. We analyzed cryo-preserved tumour 
tissue samples from 20 stage IV metastatic melanoma patients 
and 12 tissue samples from normal healthy skin (summarized 
in Supplementary Table 7, available at Carcinogenesis Online). The 
melanoma samples were grouped based on the clinical response 
of the respective patient to chemotherapy (complete response, 
stable disease or progressive disease).
We extracted total RNA from the samples and conducted 
qRT-PCR analysis for each melanoma biomarker including TRIB2 
(Figure 3A white bar). In strong support of our meta-analysis, 
we note that TRIB2 expression was significantly higher in mela-
noma samples compared to normal skin samples. Considering 
our previous results that suggested TRIB2 expression could 
be indicative of disease stage, we questioned if TRIB2 or the 
other biomarkers expression correlated with clinical progno-
sis (Figure 3B). We also questioned if TRIB2 or any of the three 
key biomarker expression identified by our ROC/AUC analysis 
correlated with clinical outcome (Figure 3C). These biomarkers 
(TRIB2, S100B, TYR and PTTG1) were selected as they were the 
strongest performers in out ROC/AUC analysis and are, in this 
analysis, the most robust biomarkers from the meta-analysis. 
Strikingly, we note that TRIB2 expression correlated strongly 
with disease response to chemotherapeutic intervention, 
where the highest average expression was observed in progres-
sive disease samples Figure 3B and C). Conversely, there is no 
correlation between the various chemotherapeutic regimens, 
the chemo-sensitivity index (CSI) and the clinical outcome 
(Supplementary Table  7, available at Carcinogenesis Online). 
The expression level of the other known melanoma markers 
showed a significant expression increase in metastatic mela-
noma samples compared to normal tissue although there was 
not a conserved grouping for any of these based on final disease 
outcome with the exception that only TYR showed a conserved 
expression change based on treatment outcome. Interestingly 
TRIB2, S100B, TYR and PTTG1 showed a statistically signifi-
cant expression difference between complete response versus 
either stable disease or progressive disease (Figure 3C). Finally, 
we questioned if TCGA database supported our ex vivo clinical 
sample studies. We observed that for any of the 13 melanoma 
biomarkers investigated in our study, only two melanoma bio-
markers (SPP1 and TYR) showed a statistically significant expres-
sion change between melanoma versus metastatic melanoma 
samples (Supplementary Figure  3, available at Carcinogenesis 
Online). Unexpectedly, within the TCGA database, TYR expres-
sion significantly decreased between primary tumour patients 
versus metastatic melanoma patient samples. While there was 
no statistically significant expression difference for any of the 
other tested biomarkers we examined whether there was a 
significant difference in gene expression in relation to patient 
survival (alive or dead) (Figure 3D), Breslow score (Figure 3E) or 
the Clark melanoma index (Figure 3F) for the three biomarkers 
(S100B, TYR and PTTG1) and TRIB2 that showed a statistically 
significant difference regarding clinical outcome (Figure  3C). 
We detected no statistically significant difference between bio-
marker expression and patient survival (Figure 3D), but we did 
note a trend for TRIB2 and TYR that show lower gene expression 
Table 1. Increased biomarker expression within melanoma














When we analysed increased gene expression for each of the 12 metastatic 
biomarkers (including TRIB2) we were able to rank the previously described 
melanoma biomarkers. Besides S100B, TRIB2 displayed the most conserved, 
increased gene expression across all three data sets across each grade of mela-
noma. The significance of the two values is ** and **, respectively. 
Table 2. ROC curve and AUC analysis of each biomarker and TRIB2
Gene
GSE3189 GSE4587 GSE7553 Overall
AUC Rank AUC Rank AUC Rank Average Rank
SPP1 0.987 1 1.00 1 0.913 1 0.967 1
TRIB2 0.964 3 0.917 6 0.867 2 0.916 2
PTTG1 0.970 2 1.000 1 0.702 6 0.891 3
MCM6 0.889 5 0.972 3 0.632 8 0.831 4
RGS1 0.737 7 0.896 7 0.803 3 0.812 5
MCM4 0.856 6 0.944 4 0.512 11 0.771 6
TYR 0.958 4 0.667 11 0.671 7 0.765 7
HSP90AB1 0.711 8 0.861 8 0.717 5 0.763 8
S100B 0.565 10 0.944 4 0.775 4 0.762 9
ERBB3 0.668 9 0.833 9 0.612 9 0.704 10
ING3 0.296 11 0.806 10 0.582 10 0.561 11
NCOA3 0.218 12 0.639 12 0.290 13 0.382 12
ING4 0.068 13 0.472 13 0.361 12 0.300 13
Talantov et al. (GSE3189), Smith et al. (GSE4587) and Riker et al. (GSE7553) data 
and probe sets were analysed for each melanoma biomarker and TRIB2 and 
within each data set, based on TP versus FP, we ranked each biomarker within 
each microarray study. Across each data set, TRIB2 was consistently one of the 
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in alive patients. The opposite trend was noted for S100B and 
PTTG1. These trends were supported by the Breslow index anal-
ysis where high TRIB2 and TYR, S100B and PTTG expression cor-
related with <3 mm Breslow thickness. However, this trend was 
not conserved for Clarks index score (Figure 3F).
Discussion
In this study, we evaluated the potential of TRIB2 to detect the 
presence and stage of human melanoma compared to 12 pre-

































































































































































































































































































































































































































































































































































































Figure 3. TCGA data analysis of TRIB2 and each biomarker including transcriptional analysis in ex vivo primary stage IV metastatic melanoma samples. (A) The aver-
age gene expression change from normal tissue compared to metastatic melanoma samples (N = 20). B shows the analysis of gene expression in melanoma samples 
(prior to chemotherapeutic administration) separated based on final clinical outcome (complete response N = 5, stable disease N = 5 and progressive disease N = 10). 
C highlights the three strongest biomarkers and TRIB2 expression based on final patient outcome (including statistical analysis between each group). For all qRT-PCR 
studies, samples were analyzed in quadruplicate and normalized to GAPDH as described in our materials and methods. For each clinical outcome, non-paired two 
tailed Student t-tests were conducted. P values are shown. Error bars indicate standard deviation (SD). (D). Gene expression from TCGA data set for TRIB2, S100B, TYR 
and PTTG1 in alive (white bars N = 231) and dead (black bars N = 140) patients. Error bars indicated are representative of standard deviation (SD). (E) Gene expression 
analysis of TRIB2, S100B, TYR and PTTG1 separated based on Breslow classification (<3 mm white bars N = 143, >3 mm black bars N = 137) groups within the TCGA dataset. 
Error bars indicated are representative of standard deviation (SD). (F) Gene expression analysis of TRIB2, S100B, TYR and PTTG1 separated based on Clark’s index (stage 
I white bars N = 5, stage II light grey bars N = 16, stage III grey bars N = 59, stage IV dark grey bars N = 127 and stage V black bars N = 46) within the TCGA dataset. Error 
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biomarkers would detect subclinical metastatic disease and 
accurately reflect tumour progression enabling a personalized 
disease management strategy and individual risk assessments 
for patients with melanoma. Although no single biomarker can 
currently predict patient’s clinical outcome several biomarkers 
have been shown to reflect some aspects of the disease (10).
As there has been low agreement between DNA microarray 
studies sourcing cell line versus tissue samples (32), we con-
ducted our meta-analysis combining datasets based on clini-
cal patient samples from both independent research groups 
and the TCGA database. Interestingly, apart from TRIB2 only 
four out of the 12 melanoma biomarkers displayed significant 
expression changes in each dataset. The poor overall correlation 
of the three microarray data sets may be somewhat surprising, 
but this has generally been observed in such meta-analyses (32). 
Whereas this characteristic might have initially casted doubts 
on microarray measurements, it has become more and more 
obvious that it can be highly beneficial to distinguish between 
true biological variability and variability merely due technical 
procedures. In fact, we have shown in a recent study that the 
divergence observed between microarray studies can be uti-
lized to produce more biologically reliable sets of differentially 
expressed genes (33).
It is important to note that S100B and TYR which turned out 
to be the most consistently over-expressed genes or having the 
strongest AUC values in the melanoma samples of our meta-
analysis are the best-studied factors among the melanoma 
biomarkers used in this work. S100B is a well-established and 
widely used immunohistochemical marker of pigmented skin 
lesions (34–36). In fact, German and Swiss guidelines recom-
mend the use of S100B as a serum marker for patients with 
lesions with a Breslow thickness of over 1 mm (10). Importantly, 
we found S100B to be the most over-expressed metastatic mela-
noma biomarker in two out of three datasets suggesting that 
the detection of its transcript level might be a sensitive method 
to detect metastatic disease in peripheral blood of patients. 
Conversely, in one dataset, TYR was the most over-expressed 
gene between normal compared to melanoma samples. While 
TRIB2 was not the most over-expressed gene in melanoma ver-
sus normal in any of the datasets, it ranked within the top three 
genes in every dataset and turned out to be the most consistent 
melanoma biomarker in our meta-analysis. We also observed 
through our ROC curve analysis that the performance computed 
by estimating AUC of TRIB2 as melanoma biomarker is consider-
ably better in large datasets [Talantov et al. (GSE3189), (n = 70) (27) 
and Riker et al. (GSE7553), (n = 80] (29) when compared to other 
markers such as MCM6 and MCM4 which are ranked higher than 
TRIB2 in smaller dataset [Smith et  al. (GSE4587), (n  =  15)] (28). 
Importantly, both S100B and TRIB2 displayed a gradual, highly 
significant increase in their expression level for each melanoma 
grade analyzed.
Nevertheless, it is important to stress that finding robust bio-
markers for disease progression and staging remains extremely 
challenging, a caveat highlighted by the analysis of other far 
more bona-fide biomarkers (such as S100B and TYR) that show 
incoherencies in disease staging when comparing the results of 
the microarray data with the TCGA dataset. This caveat is also 
indicated by the results for TRIB2 (as well as for any of these 
tested biomarkers), as no statistically significant difference 
based on patient survival (alive/dead), Breslow or Clark index 
was detected. However, some trends in expression profiles could 
be noted within this large dataset. Considering the difficulty in 
detected consistent expression changes of individual genes, it 
might be necessary to carry out simultaneous assessment of 
several markers to gain a more robust disease staging definition.
Besides analysing published expression data, we also vali-
dated our findings in a number of ex vivo melanoma samples. 
Importantly, a strong correlation of TRIB2 expression with 
treatment response por chemotherapeutic intervention was 
observed. Taken altogether our results suggest that the meas-
urement of TRIB2 expression might be useful to both diagnose 
human melanoma and if present, disease stage. Stringent clini-
cal analysis should validate the usefulness of monitoring TRIB2 
expression for melanoma staging in particular the capability to 
detect the presence of melanoma metastasis in regional lymph 
nodes. Since the presence of regional lymph node metastasis is 
the strongest predictor of relapse rates and survival, accurate 
identification of metastatic disease within the regional lymph 
nodes is of key importance to identify patients which should 
be treated with adjuvant therapy. Standard procedure for the 
examination of regional lymph nodes involves histopathologi-
cal examination by haematoxylin and eosin and immunohisto-
chemical staining. However, this approach may underestimate 
the presence of metastatic disease. The effort to develop more 
accurate and sensitive methods to identify micro-metastatic 
disease in the regional lymph nodes or the peripheral blood led 
to the introduction of molecular techniques. The identification 
of circulating melanoma cells via the PCR-based detection of 
TYR in peripheral blood has been introduced in the early 90s and 
allowed for a 10 000-fold increased sensitivity when compared 
to immunohistochemical analysis (14). However, the clinical 
value of this procedure is limited by the proportion of patients 
with clinical confirmed distant metastasis being TYR negative in 
almost all the studies. It has been suggested that the combina-
tion of TYR with additional melanoma specific molecular mark-
ers could increase the accuracy of detection (37).
Our present work suggests that TRIB2 might not only be use-
ful as a marker to monitor the progression of cutaneous skin 
lesions but also opens the possibility to test its usefulness for 
combinational use with other biomarkers to detect circulating 
tumour cells in lymph nodes or peripheral blood. Furthermore, 
the striking correlation between the expression level of TRIB2 and 
the response to different chemotherapeutic regimens suggests 
its utility as a biomarker of chemotherapy response. Predictive 
biomarkers may help to guide therapy in a personalized medi-
cine strategy selecting those patients more likely to benefit from 
chemotherapy while avoiding toxic effects in those patients not 
deriving benefit from chemotherapy (38). It should be noted that 
the current work only lays the groundwork for future large-scale 
studies in independent data sets and verification in a clinical 
setting preferentially from clinical trials. These studies should 
also address the correlation of TRIB2 with the main clinical and 
histopathological prognosis factors such as tumour depth, diam-
eter, ulceration, anatomic site and sentinel-lymph node status 
and ultimately with patient survival. A further understanding of 
TRIB2 cellular functions and how these could impact cell trans-
formation and disease progression would identify a wide range 
of novel therapeutic targets that could significantly reduce the 
mortality associated with metastatic melanoma.
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Supplementary Tables 1–7 and Figures 1–3 can be found at 
http://carcin.oxfordjournals.org/
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